BSECompany Update4d ago · 14 Nov 2026, 04:33 pm

Statement of deviation or variation for the quarter ended on September 30, 2026 on the use of proceeds of funds raised through Qualified institutional placement (QIP)

Orchid Pharma Ltd · 524372

✦ AI SummaryResults

Orchid Pharma Ltd has filed a statement of deviation or variation for the quarter ended September 30, 2026, on the use of proceeds of funds raised through Qualified Institutional Placement (QIP). The company has reallocated the QIP proceeds from the API Facility in Alathur to other projects, citing changes in the business environment and strategic requirements.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk6/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Orchid Pharma Ltd - 524372 - Statement Of Deviation Or Variation For The Quarter Ended September 30, 2026 On The Use Of Proceeds Of Funds Raised Through Qualified Institutional Placement (QIP)

Attachments (1)

📄

10cc6f1d-d25f-4a1a-b8ac-f6a65d050598.pdf

pdf

Download →
View document text
OrchidPharm~~ -- A DhanukaGroup Company ----------------------------------- November 14, 2026 National Stock Exchange of India Limited, SSE Limited Exchange Plaza, Sandra Kurla Complex, Phiroc Jeejeebhoyi owers, Sandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Statement of deviation or variation for the quarter ended September 30, 2026 on the use of proceeds of Funds raised through Qualified Institutional Placement (QiP) Dear Sir/Madam, With reference to aforesaid subject and pursuant to Regulation 32 of the SESI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SESI Master Circular SESI/ HO/49j14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, Statement of Deviation for the quarter ended September 30, 2026, duly reviewed by the Audit Committee of the Company is attached herewith. You are requested to kindly take the same on record For Orchid Pharma Limite~ p ya Co pany Secretary & Compliance Officer embership No.: F10698 +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1. DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151. 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~~ -- A DhanukaGroup Company ---,.....--------------------------------- STATEMENT OF DEVIATION OR VARIATION UNDER REGULATION 32 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REOUIREMENTS1REGULATIONS, 2015 FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIfIED INSTITUTIONS PLACEMENT ETC . Name of listed entity Orchid Pharma Limited Mode of Fund Raising Qualified Institutions Placement Date of Raising Funds June 27, 2023 Amount Raised RsAOO Crores Report fiied for Quarter ended September 30, 2026 Monitoring Agency Applicable Monitoring Agency Name, if applicable Care Ratings Limited Is there a Deviation / Variation in use Yes of funds raised If yes, whether the same is pursuant to Yes change in terms of a contract or objects, which was approved by the shareholders If Yes, Date of shareholder Approval September 20, 2025 Explanation for the Deviation I In view of changes in the business environment Variation and to meet current strategic requirements, the Company has modified the allocation of the QIP Proceeds. The commencement of "new block at API Facility of the Company in Alathur" project has been postponed to a later stage. Therefore, QIP Proceeds allotted to API Facility in Alathur has been reallocated with the approval of shareholders at the AGM held on September 30, 2025, to mitigate such additional financial burden, improve profit and ensure the best possible utilization of the QIP proceeds in the overall interest of the Company and its shareholders. Comments of the Audit Committee after As per attached Annexure review Comments of the auditors, if any NA Objects for which funds have been l. Investment in our wholly owned Subsidiary, raised and where there has been a Orchid Bio-Pharma Limited, ("OBPL") deviation, in the following table for setting up a new manufacturing facility in Jammu ("Jammu Manufacturing Facility"); 2. Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by our Company; 3. Funding capital expenditure requirements for setting up a new block at API Facility of the Company in Alathur, Tamil Nadu; and 4. General corporate purposes. ---------'!ik-- - +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~W -- A DhanukaGroup Company ------------------------------------- I Sr. I Original Object I Modified Original Modified I Funds Amount of I Rema No , Object, Allocatio allocatio I Utilised Deviation/ rks ii if any n (Rs. in n, , (Rs. in Variation any (Rs. in Lakhs) if any Lakhs) for the Lakhs) (Rs. in quarter lakhs) according applicable object (Rs. in Lakhs) 1 Investment in OBPL for No 9000 13500 13500 setting up Jammu Manufacturing Facility 2 Repayment/prepayme No 14100 19546 19546 o nt, in full or in part, of certain outstanding borrowings availed by our Company 3 Funding capital No 9982 36 36 expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu 4 General corporate No 6098* 6372 6372 0 purposes ("GCP") As per the QIP offer document the amount allocated for GCP was Rs.6098 Lakhs which was on the basis of proposed net proceeds after issue expenses, being Rs.39180 Lakhs. However, net Proceeds transf~E.r..ed to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39;1'80 Lakhs, therefore the GCP was revised to Rs.274 lakhs has been included in the GCP and th'erefore the GCP balance was revised to Rs.6372 Lakhs. &. Compliance Officer +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~W -- A Dhanuka Group Company --------------------------------------- Annexure So· i Para I Particulars/ Item Head Comments of Monitoring Comments of Audit I No No. of Agency Committee Report 1 3 Whether all utilization is as The company revised the · The comments of f'.1onitoring per the disclosure in the allocation of QIP proceeds Agency are self-explanatory Offer Document? among the objects specified in the offer document, pursuant to shareholders' approval obtained through the AGM resolution dated September 20, 2025. Accordingly, the utilisation of funds is now being undertaken in line with the revised allocation schedule. 2 3 Whether shareholder Change in allocation of funds The comments of Monitoring approval has been obtained towards the objects of the Agency are self-explanatory in case of material deviations issue was approved by from expenditures disclosed shareholders vide AGM in the Offer Document? resolution dated September 20, 2025. 3 3 Whether the means of The company revised the The comments of Monitoring finance for the disclosed allocation of QIP proceeds Agency are self-explanatory objects of the issue have among the objects specified changed? in the offer document, pursuant to shareholders' approval obtained through the AGM resolution dated September 20, 2025. Accordingly, the utilisation of funds is now being undertaken in line with the revised allocation schedule 4 3 Whether all No specific list of statutory/ The comments of Monitoring Government/statutory Govt Approvals was Agency are self-explanatory approvals related to the mentioned in the offer object(s) have been document for the purpose of obtained? monitoring. As per the AGM dated Sep 20, 2025, no further investment is expected towards Alathur proiect from QIP proceeds. 5 3 Whether all arrangements The company has spent Rs. The comments of Monitoring pertaining to technical 3.77 crores towards Agency are self-explanatory aSSistance/collaboration are technical know-how. in operation? 6 3 Are there any There is significant delay in The Land acquisition task has favorable/unfavorable the implementation of the been given to Land events affecting the viability manufacturing facility under aggregator who is getting the of these object(s)? Orchid Bio Pharma Limited in land from various farmers. Jammu, Commercial Getting the agreement ci~erations are now expected signed from various farmers to commence by February has taken [Showing first 8,000 characters — download PDF for full document]